COMPANY PROFILE / #3484
Atmo Biosciences
Box Hill, AustraliaVenture Capital-Backed
OVERVIEW
Manufacturer of an ingestible gas-sensing capsule designed for monitoring gut health and microbiome function. The company's capsule provides real-time measurement of gaseous biomarkers, non-invasive assessment of gut transit times, a radiation-free diagnostic alternative, continuous monitoring during normal daily activities, multimodal onboard sensor signals for contractility mapping, enabling gastroenterologists to diagnose motility disorders quickly and accurately without invasive procedures.
已融资36.45
最新估值39.96
员工数31
成立年份2012
公司概况
- Companies
- Atmo Biosciences
- Description
- Manufacturer of an ingestible gas-sensing capsule designed for monitoring gut health and microbiome function. The company's capsule provides real-time measurement of gaseous biomarkers, non-invasive assessment of gut transit times, a radiation-free diagnostic alternative, continuous monitoring during normal daily activities, multimodal onboard sensor signals for contractility mapping, enabling gastroenterologists to diagnose motility disorders quickly and accurately without invasive procedures.
- Website
- www.atmobiosciences.com
- HQ Location
- Box Hill, Australia
- Year Founded
- 2012
- Keywords
- biotechnology based, diagnostic care, gut care, gut health, personalized care, remote monitoring
- Competitors
- AnX Robotica
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 36.45
- First Financing Date
- 01-Jan-2018
- First Financing Size
- 0.08
- First Financing Valuation
- —
- Last Financing Date
- 12-Aug-2026
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 12.00
- Last Financing Valuation
- —
- Last Financing Status
- Completed
- Last Known Valuation
- 39.96
- Last Known Valuation Date
- 06-Nov-2023
- Last Known Valuation Deal Type
- Secondary Transaction - Private
- Valuation Estimate
- 43.42
- Valuation Estimate Growth Rate
- 8.66%
- Active Investors
- Alium Capital Management, ANDHealth, BioCurate, Breakthrough Victoria, Brisbane Angels, Johnson & Johnson Innovation - JLABS, Otsuka (IT Consulting and Outsourcing), Otsuka Pharmaceutical
- # Active Investors
- 8
- Acquirers
- —
团队与联系人
- Employees
- 31
- Employee Growth %
- 24.00%
- Employee History
- 2026: 31, 2025: 25, 2024: 32, 2023: 30, 2022: 25, 2021: 13
- Primary Contact
- Malcolm Hebblewhite
- Primary Contact Title
- Co-Founder, Chief Executive Officer, President, Managing Director & Board Member
- Primary Contact Email
- malcolm.hebblewhite@atmobiosciences.com
- Primary Contact Phone
- +61 (0)4 1846 5728
增长与经营
- Revenue
- 2.97
- Revenue Growth %
- 82.74%
- Growth Rate
- 0.18%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 91
- Size Multiple
- 5.96x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 84
- Majestic Referring Domains
- 209
- SimilarWeb Unique Visitors
- 308
- SimilarWeb Unique Visitors Change
- 64
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 19%
- Success Probability Over Time – 3 Year
- 36%
- Success Probability Over Time – 5 Year
- 45%
记录来源：public.companies · 原始序号 #3484 · 所有字段均按数据库原值展示。